NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The drug has a patchy history with the health service, having been previously rejected on cost ef...
Original Article: NHS U-turns on Afinitor for TSC-related epilepsy